Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Insulin for Pemphigus Vulgaris Lesions
NCT07461103Phase 2Completed
- Sponsor
- Alexandria University
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of insulin glargine and Generex Oral-lyn in pemphigus vulgaris (PV) (3 arms), sponsored by Alexandria University. Primary endpoint: Time to Complete Healing at 14 days. Started Jun 2024; status: completed.
02
Drugs
insulin glargineGenerex Oral-lyn
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT07461103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07461103.